2-(4-苯氧基苯基)-乙胺 | 51179-05-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-苯氧基苯基)-乙胺
• 中文别名: 2-(4-苄氧基苯基)-乙胺
• 英文名称: 2-(4-(benzyloxy)phenyl)ethanamine
• 英文别名: 2-(4-benzyloxyphenyl)ethyl amine；o-benzyltyramine；2-(4-(benzyloxy)phenyl)ethan-1-amine；2-(4-(phenylmethoxy)phenyl)ethylamine；2-(4-Benzyloxy-phenyl)-ethylamine；2-(4-phenylmethoxyphenyl)ethanamine
• CAS: 51179-05-6
• 化学式: C₁₅H₁₇NO
• mdl: MFCD00025607
• 分子量: 227.306
• InChiKey: MKKMZZXGIORPMU-UHFFFAOYSA-N

物化性质

• 溶解度：
  溶于氯仿；二氯甲烷；乙酸乙酯;甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2922199090

反应信息

• 作为反应物：
  描述：

  2-(4-苯氧基苯基)-乙胺 在 sodium tetrahydroborate 、 五氯化磷 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 8.5h， 生成 6-(benzyloxy)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  苄基四氢异喹啉的光气化：一种新的berbines和berbin-8-ones合成方法

  摘要：

  据报道，通过berbin-8-ones可以合成一种新的贝宾环骨架。用光气处理1-苄基-1,2,3,4-四氢异喹啉1a-d，得到一系列新的N-氯甲酰基衍生物2a-d。在路易斯酸催化剂的存在下，这些化合物的分子内闭环以良好的产率提供了berbin-8-ones 3a-d。讨论了环化催化剂的选择。用氢化锂铝还原产物3a-d得到了小bin碱4a-d。水解小bin 4b，c生成新的3-羟基小hydroxy 4e，f。制备新的起始苄基四氢异喹啉描述图1b，c。

  DOI：

  10.1016/s0040-4020(01)83481-5
• 作为产物：
  描述：

  2-(4-苯甲氧基苯基)乙醇 在 sodium azide 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 27.0h， 生成 2-(4-苯氧基苯基)-乙胺
  参考文献：
  名称：

  Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors

  摘要：

  Concerned by the devastating effects of Alzheimer's disease, and the lack of effective drugs, we have carried out the design of a series of tacrine-phenolic heterodimers in order to tackle the multifactorial nature of the disease.Hybridization of both pharmacophores involved the modification of the nature (imino, amino, ether) and the length of the tether, together with the type (hydroxy, methoxy, benzyloxy), number and position of the substituents on the aromatic residue. Title compounds were found to be strong and selective inhibitors of human BuChE (from low nanomolar to subnanomolar range), an enzyme that becomes crucial in the more advanced stages of the disease.The lead compound, bearing an ether-type tether, had an IC50 value of 0.52 nM against human BuChE, and a selectivity index of 323, with an 85-fold increase of activity compared to parent tacrine; key interactions were analysed using molecular modelling. Moreover, it also inhibited the self-aggregation of A beta 42, lacking neurotoxicity up to 5 mu M concentration, and showed neuroprotective activity in primary rat neurons in a serum and K+ deprivation model, widely employed for reproducing neuronal injury and senescence. Moreover, low hepatoxicity effects and complete stability under physiological conditions were found for that compound.So, overall, our lead compound can be considered as a promising multitarget-directed ligand against Alzheimer's disease, and a good candidate for developing new drugs. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.07.053

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] PROGRANULIN MODULATORS AND METHODS OF USING THE SAME<br/>[FR] MODULATEURS DE LA PROGRANULINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARKUDA THERAPEUTICS

  公开号：WO2020252222A1

  公开（公告）日：2020-12-17

  Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal dementia (FTD).

  本文件提供了调节颗粒蛋白的化合物及其在颗粒蛋白相关疾病中的使用方法，例如额颞痴呆（FTD）。
• Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
  申请人：——

  公开号：US20020032238A1

  公开（公告）日：2002-03-14

  The present invention relates to substituted piperazine derivatives of general formula 1 wherein R 1 to R 7 are defined herein, the isomers and salts thereof, particularly the physiologically acceptable salts thereof, which are valuable inhibitors of the microsomal triglyceride-transfer protein (MTP), medicaments containing these compounds and their use, as well as the preparation thereof.

  本发明涉及一般式1的取代哌嗪衍生物，其中R1至R7在此处定义，其异构体和盐，特别是其生理上可接受的盐，这些盐是微粒体三酰甘油转移蛋白（MTP）的有价值的抑制剂，含有这些化合物的药物以及它们的用途，以及其制备。
• Benzopyranes as potassium channel openers
  申请人：Pfizer Inc.

  公开号：US05677324A1

  公开（公告）日：1997-10-14

  The present invention relates to compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein the dashed line represents an optional covalent bond; X is O, NH, S or a direct link; R.sup.3 is hydroxy when the dashed line does not represent a covalent bond and R.sup.3 is absent when the dashed line represents a covalent bond; R.sup.4 is (a), when X is O, a group of formula (i), (b), when X is O, NH or S, optionally substituted hydroxyphenyl, (c) an optionally substituted 4- to 7-membered heterocyclic ring, or (d), when X is NH, a group of formula (ii). The compounds are useful for the treatment of disease associated with the altered tone or motility of smooth muscle. ##STR1##

  本发明涉及式(I)的化合物及其药学上可接受的盐，其中虚线代表可选的共价键；X为O、NH、S或直接连接；当虚线不代表共价键时，R.sup.3为羟基，当虚线代表共价键时，R.sup.3不存在；当X为O时，R.sup.4为(a)，为式(i)的基团，当X为O、NH或S时，为可选取代的羟基苯基(b)，为可选取代的4-至7-成员杂环环(c)，或当X为NH时，为式(ii)的基团(d)。这些化合物对于治疗与平滑肌张力或运动异常相关的疾病是有用的。
• Compounds and pharmaceutical use thereof
  申请人：Japan Tobacco Inc.

  公开号：US06017919A1

  公开（公告）日：2000-01-25

  The compounds of the formula (I) ##STR1## wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and pharmaceutical use thereof. The Compound (I) and pharmaceutically acceptable salts thereof of the present invention selectively act on cannabinoid receptors, particularly peripheral receptors, cause less side effects on the central system, and have superior immunoregulating action, antiinflammatory action, antiallergic action and therapeutic effect on nephritis. Therefore, they are useful as cannabinoid receptor, particularly peripheral cannabinoid receptor activators and antagonists, immunoregulators, therapeutic agents for autoimmune diseases, antiinflammatory agents, antiallergic agents and therapeutic agents for nephritis.

  公式（I）##STR1##中的化合物，其中每个符号如说明书中所定义，其药用可接受的盐及其医药用途。本发明的化合物（I）及其药用可接受的盐对大麻素受体具有选择性作用，尤其是外周受体，对中枢系统的副作用较小，并且具有卓越的免疫调节作用、抗炎作用、抗过敏作用和对肾炎的治疗效果。因此，它们作为大麻素受体，尤其是外周大麻素受体的激动剂和拮抗剂，免疫调节剂，自身免疫性疾病的治疗剂，抗炎剂，抗过敏剂和肾炎的治疗剂是有用的。